拉考沙胺静脉推注给药的安全性与效率
该单中心回顾性队列研究纳入2016年6月至2017年7月接受拉考沙胺静脉滴注(n=88)或静脉推注(n=78)的患者,比较两种给药方式的安全性与效率。主要安全结局为每次给药后2小时内记录的输注部位反应、低血压(收缩压<90 mmHg)和心动过缓(心率<50次/分),两组低血压(8% vs 10.3%)和心动过缓(2.3% vs 2.6%)发生率相似(P>0.05),PR间期延长各1例,无输注反应记录。主要效率结局为医嘱审核至给药时间,静脉推注组中位时间显著缩短(35分钟 vs 1小时49分钟,P<0.001)。结论认为静脉推注拉考沙胺的不良反应发生率与静脉滴注相似,且给药更高效。
要点
- 静脉推注拉考沙胺组与静脉滴注组低血压(收缩压<90 mmHg)发生率分别为8%和10.3%,差异无统计学意义(P>0.05)。
- 静脉推注组与静脉滴注组心动过缓(心率<50次/分)发生率分别为2.3%和2.6%,差异无统计学意义(P>0.05)。
- 两组各仅1例记录到PR间期延长,均无输注部位反应记录。
- 静脉推注组从医嘱审核到给药的中位时间显著短于静脉滴注组(35分钟 vs 1小时49分钟,P<0.001)。
- 该研究为单中心回顾性队列,样本量静脉滴注组88例、静脉推注组78例,结论需在更广泛人群中验证。
适用人群与场景
- 2016年6月至2017年7月单中心接受拉考沙胺静脉给药(静脉滴注或静脉推注)的患者。
处置流程与药物剂量
- 静脉推注组:拉考沙胺不稀释直接静脉推注;静脉滴注组:按药品说明书稀释后30-60分钟输注。
- 原文提及近期文献显示不稀释给药最大速率80 mg/min(Kellinghaus等,Acta Neurol Scand 2011;123:137-141)具有安全性,但本研究未报告具体推注速率。
研究设计与关键结果
- 研究类型:单中心回顾性队列研究;样本量:静脉滴注组88例,静脉推注组78例;人群:接受拉考沙胺静脉给药的患者。
- 主要安全结局:低血压(收缩压<90 mmHg)发生率静脉滴注组8% vs 静脉推注组10.3%,心动过缓(心率<50次/分)发生率2.3% vs 2.6%,差异均无统计学意义(P>0.05)。
- 次要安全结局:PR间期延长每组各1例,无输注部位反应记录。
- 主要效率结局:医嘱审核至给药中位时间静脉推注组35分钟 vs 静脉滴注组1小时49分钟,静脉推注组显著缩短(P<0.001)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究;未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于需要紧急控制癫痫发作的患者,静脉推注拉考沙胺可能缩短给药时间,且不良反应发生率与静脉滴注相似。
- 该研究为单中心回顾性设计,样本量有限,作者结论为静脉推注拉考沙胺的不良反应发生率与静脉滴注相似且给药更高效。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND/OBJECTIVE: Intravenous (IV) lacosamide use for status epilepticus has increased in recent years and is recommended for refractory status epilepticus by current guidelines. Per the lacosamide package labeling, the preferred route of administration is diluted and infused over 30-60 min; however, administration undiluted is also acceptable and recent literature demonstrated safety at a maximum rate of 80 mg per minute (Kellinghaus et al. in Acta Neurol Scand 123:137-141, 2011). Undiluted administration as an IV push has potential to increase efficiency of administration to patients needing urgent seizure control since it may be dispensed from automatic dispensing cabinets in patient care areas. This study aims to compare safety outcomes and efficiency of administration in patients receiving lacosamide IV push compared to IV piggyback.
METHODS: We present a single-center, retrospective cohort study of patients receiving lacosamide via IV piggyback or IV push from June 2016 to July 2017. Baseline characteristics, data related to potential safety concerns and timing of ordering, verification, and administration were collected. The primary safety outcomes were incidence of infusion site reactions, hypotension (systolic blood pressure [SBP] < 90 mm Hg), and bradycardia (heart rate [HR] < 50 beats per minute) documented within 2 h of each lacosamide dose. Secondary safety outcomes included the incidence of PR interval prolongation in patients with at least one electrocardiogram measured. The primary efficiency outcome was the time between order verification and administration.
RESULTS: Patients in the IV piggyback (n = 88) and IV push (n = 78) groups had similar baseline characteristics, initial dose, SBP, and HR. Hypotension (8 vs. 10.3%) and bradycardia (2.3 vs. 2.6%) rates were similar among both groups (p > 0.05). Only one patient in each group had documented PR prolongation, and no documented infusion reactions occurred. Median time from order verification to administration was significantly reduced in the IV push group (35 min vs. 1 h 49 min; p < 0.001).
CONCLUSIONS: Administration of lacosamide via IV push results in similar adverse effect rates to IV piggyback preparations with more efficient time to administration.
参考来源
- Davidson KE, Newell J, Alsherbini K, et al. Safety and Efficiency of Intravenous Push Lacosamide Administration. Neurocrit Care. 2018. PMID: 29949010. doi:10.1007/s12028-018-0560-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。